on BIOSYNEX (EPA:ALBIO)
BIOSYNEX SA: 2025 Annual Report and Outlook for 2026
BIOSYNEX SA ended 2025 with revenue of €95.2 million, a 6% decrease compared to 2024. This decline is due to unfavorable exchange rate effects and the discontinuation of unprofitable activities. Despite this, the company recorded an improvement in its gross margin, reaching 62.2% of revenue, thanks to refocusing and cost-reduction measures.
The first quarter of 2026 got off to a difficult start with an 11% drop in revenue amid an unstable economic environment. BIOSYNEX continues to streamline its operations to return to positive EBITDA. Uncertainties persist regarding the company's ability to continue as a going concern, with the auditors expressing reservations about the valuation of intangible assets.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news